Biocartis NV logo.jpg
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region
May 06, 2024 01:00 ET | Biocartis NV
PRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region Biocartis (Mechelen,...
Dyadic Logo Current.jpg
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
April 30, 2024 16:30 ET | Dyadic International, Inc.
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
George Medicines Logo.JPG
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director
April 29, 2024 07:00 ET | George Medicines
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet...
baylor-logo-wire-1200x628.jpg
Using AI to Improve Diagnosis of Rare Genetic Disorders
April 25, 2024 09:19 ET | Baylor Genetics
Diagnosing rare Mendelian disorders is a labor-intensive task, even for experienced geneticists. Investigators at Baylor College of Medicine are trying to
Current paradigm of HER2 expression scoring
Promising perspectives for the application of SDS Optic’s inPROBE technology platform for protein expression determination
April 25, 2024 08:00 ET | SDS Optic S.A.
SDS Optic's positive results from the Part I Clinical Trial of the novel optic fiber probe, inPROBE®, in vivo real-time molecular diagnostic technology.
01-Logotipo.png
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
April 25, 2024 03:00 ET | DeepUll
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024 UllCORE is designed to transform life-saving clinical decision making for sepsis...
22157.jpg
Global Market for Exosome Diagnostics, Therapeutics, and Research Tools (2021-2028) Featuring Bio-Techne, Exosomics, and System Biosciences - An Evaluation of New Commercial Opportunities and Emerging Trends
April 24, 2024 04:20 ET | Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Exosome Diagnostics, Therapeutics and Research Tools: Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market...
22157.jpg
Global Sleep Tech Device Market Trends, Forecast and Competitive Analysis, 2018-2023 and 2024-2030
April 19, 2024 09:31 ET | Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "Sleep Tech Device Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
Global Cancer Diagnostics Market
Global Cancer Diagnostics Market Set to Reach US$ 280.37 Billion by 2030 with Illumina, Abbott Laboratories, Thermo Fisher Scientific, QIAGEN, Roche, Pfizer, Koninklijke Philips,& bioMérieux Leading
April 19, 2024 05:17 ET | Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis" report...
Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension
Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
April 18, 2024 11:00 ET | Recor Medical
Palo Alto, CA, April 18, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), announce the first commercial...